Capital Insights
Targeting the Untouchable: The High-Stakes Race to Outsmart ‘Invisible’ Tumors
Percheron Therapeutics is developing the drug HMBD-002 to target the VISTA protein, aiming to make previously “invisible” cancers visible to the immune system. The company is preparing for its critical Phase 2 human trials in 2026 after successful Phase 1 results showed tumor shrinkage.
The “Anti-Botox” Breakthrough: How a Rural Doctor is Using Tetanus to Help the World Breathe
In the sweltering heat of a rural hospital in Northern India, a young medical student named Tony Sasse witnessed something most Western doctors only read about in textbooks: the terrifying, raw power of tetanus. He watched patients struggle with “lockjaw,” their muscles frozen in a state of hyper-active, agonising contraction. Most saw a deadly disease. […]
Solving Myopia: From the Playground to the Global Stage
For John Nguyen, the moment of clarity did not happen behind a phoropter in a darkened consulting room. It happened at home, watching the daily struggle between screen time and sunshine that defines modern parenting. As an optometrist and founder of Luxi Health, Nguyen knows the clinical data well. He understands that the world is […]
The “Screen Time” Pandemic: Why the World’s Eyeballs are Getting Too Long
With nearly half the world projected to be myopic by 2050, Eyerising International is pioneering a “disease-modifying” solution using low-level red light therapy. The Australian MedTech firm is currently raising $5 million to fund its global expansion and entry into the massive adult treatment market.
Forget antibiotics: Why the next big medical breakthrough is a beam of light
Lindo Life Science, founded by Robert Gangi, is changing the battle against antimicrobial resistance (AMR) with the Lindo Tube, which uses occupant-safe antimicrobial blue light to shatter 99.9% of bacteria. This breakthrough prevents Ventilator-Associated Pneumonia (VAP), a secondary infection affecting nearly one in four intubated patients, and has been validated by a collaboration with the Mayo Clinic.
Why the Future of Heart Health is ‘Cuffless’
After 25 years in the Emergency Room, Dr. Joe is pioneering a new era in heart health with Zaplutus Health’s Ora Connect, a revolutionary ‘peel-and-stick’ wearable providing hospital-grade, continuous, cuff-less blood pressure data to transform patient care both inside and outside the hospital.
Inside the Australian Life Sciences Boom: Renowned Investors, World-Class Partners, World-Leading Breakthroughs
The Australian life sciences sector is experiencing an unprecedented boom, marked by world-leading partnerships, rapid regulatory progress, and significant capital investment. The Emergence Preview Series showcased companies with technologies already in clinical trials and backed by renowned global institutions and investors. This moment feels different due to the maturity and global reach of Australian life sciences innovation.
The $210 Billion Secondary Market: Why Private Equity’s Third Exit Just Became Mainstream
The Liquidity Crisis That Changed Everything The private equity secondary market crossed $210 billion in transaction volume in 2025. This represents a fundamental shift in how limited partners access liquidity. For eight consecutive quarters, distributions to LPs hovered in single digits as a percentage of NAV. This matched levels last seen during the Global Financial […]
The $3.5 Trillion Succession Wave: Why 48% of Australian Business Owners Are About to Destroy Value
Australia’s Largest Wealth Transfer Has No Exit Plan Australian business succession planning is broken. An estimated $3.5 trillion in assets will pass from Baby Boomers to younger generations over the next two decades. The numbers reveal a crisis. 48% of Baby Boomer business owners plan to exit within five years. Only 24% have formal succession […]
Backed By Leading Investment Groups and Family Offices
